Login to Your Account

Neostem, Cellular Biomed ink liver cancer immunotherapy deal

By Shannon Ellis
Staff Writer

Tuesday, May 20, 2014
SHANGHAI – Neostem Inc. signed an exclusive license agreement with Cellular Biomedicine Group, of Shanghai, for its patient-specific immunotherapy (DC-TC) to treat late-stage hepatocellular carcinoma (HCC) in China, home to more than 45 percent of the world's HCC patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription